Legend Biotech Corporation (LEGN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Legend Biotech Corporation (LEGN) closed at USD 19.04 on 2026-10-14, a change of -41.5 % over the past year, with a market capitalization of USD 3.85B.

Legend Biotech Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Legend Biotech Corporation key figures

Previous close

USD 19.04 (2026-10-14)

1-year change

-41.5 %

Market cap

USD 3.85B

Enterprise value

USD 3.15B

P/E ratio (trailing)

-34.14

P/E ratio (forward)

18.86

EPS (trailing)

-0.58

EPS (forward)

1.05

PEG ratio

n/a

Price to book

3.12

Revenue growth

51.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.36

Employees

3,200

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Legend Biotech Corporation

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Legend Biotech Corporation and compare it with other stocks.